Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models

Journal of Alzheimer's Disease

Volumn 36, Issue 4, 2013, Pages 637-657

  Saydoff, Joel A ^a   Olariu, Ana ^a   Sheng, Jin ^a   Hu, Zhongyi ^a   Li, Qin ^a   Garcia, Rolando ^a   Pei, Jiong ^a   Sun, Grace Y ^b   Von Borstel, Reid ^a  

^a Wellstat Therapeutics Corporation   (United States)

^b University of Missouri   (United States)

Author keywords

Alzheimer's disease; cognition; inflammation; lipid peroxidation; mitochondria; neurodegenerative diseases; stroke; uridine

Indexed keywords

CERAMIDE; HYDROGEN PEROXIDE; MITOCHONDRIAL DNA; PN 401; PRODRUG; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIDINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ASSOCIATIVE MEMORY; BLOOD BRAIN BARRIER; CELL HYPOXIA; CELL SURVIVAL; CONDITIONING; CONTROLLED STUDY; CYTOTOXICITY; DECLARATIVE MEMORY; DNA DAMAGE; DRUG EFFECT; FEAR; FEMALE; FOOD PREFERENCE; FOOTSHOCK; FREEZING; HABITUATION; HIPPOCAMPUS; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID PEROXIDATION; LOCOMOTION; MAZE TEST; MEMORY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE FIBER GROWTH; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OLFACTORY MEMORY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REARING; RECOGNITION; ROTAROD TEST; SHORT TERM MEMORY; SMELLING; SOCIAL BEHAVIOR; WORKING MEMORY;

ALZHEIMER DISEASE; ANIMALS; CELL LINE, TUMOR; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GERBILLINAE; HUMANS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PRODRUGS; STROKE; URIDINE;

EID: 84881463496     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130059     Document Type: Article

References (101)

1. Mecocci P, MacGarvey U, Kaufman AE,Koontz D, Shoffner JM,Wallace DC, BealMF(1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34, 609-616.
2. Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich ME,Morales L (2009) Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 41, 1989-2004.
3. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 101, 10726-10731.
4. Gibson GE, Blass JP, Beal MF, Bunik V (2005) The alphaketoglutarate- dehydrogenase complex: A mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol 31, 43-64.
5. Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63, 2179-2184.
6. Curti D, Rognoni F, Gasparini L, Cattaneo A, Paolillo M, Racchi M, Zani L, Bianchetti A, Trabucchi M, Bergamaschi S, Govoni S (1997) Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci Lett 236, 13-16.
7. Gibson GE, Park LC, Sheu KF, Blass JP, Calingasan NY (2000) The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem Int 36, 97-112.
8. Beal MF (1992) Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol 2, 657-662.
9. Amatniek JC, HauserWA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47, 867-872.
10. Palop JJ, Chin J, Roberson ED,Wang J, ThwinMT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711.
11. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A,TanilaH(2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29, 3453-3462.
12. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
13. McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J Alzheimers Dis 9, 271-276.
14. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30, 107-120.
15. Eckert A, Schulz KL, Rhein V, Gotz J (2010) Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol 41, 107-114.
16. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C, Masters CL, Volitakis I, Li QX, Laughton K, Hubbard A, Cherny RA, Gibson B, Bush AI (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2, e536.
17. Diana FF, Silva Esteves AR, Oliveira CR, Cardoso SM (2011) Mitochondria: The common upstream driver of A- and tau pathology in Alzheimer's disease. Curr Alzheimer Res 8, 563-572.
18. Swerdlow RH, Khan SM (2009) The Alzheimer's disease mitochondrial cascade hypothesis: An update. Exp Neurol 218, 308-315.
19. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
20. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, SternY,Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
21. Scarmeas N, Albert M, Brandt J, Blacker D, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Wegesin D, Marder K, Bell K, Honig L, Stern Y (2005) Motor signs predict poor outcomes in Alzheimer disease. Neurology 64, 1696-1703.
22. Saydoff JA, Liu LS, Hu ZY, von Borstel RW (2004) Uridine prodrug PN401 has beneficial effects in models of Alzheimer's disease, hypoxia and oxidative stress. Neurobiol Aging 25, S213.
23. Saydoff JA, Liu LS, Garcia RAG, Hu ZY, Li D, von Borstel RW (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res 994, 44-54.
24. Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel RW, Saydoff JA, Browne SE, Beal MF (2004) Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Med 6, 87-92.
25. Garcia RA, Liu L, Hu Z, Gonzalez A, von BorstelRW, Saydoff JA(2005) Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. Brain Res 1066, 164-171.
26. Connolly GP, Duley JA (1999) Uridine and its nucleotides: Biological actions, therapeutic potentials. Trends Pharmacol Sci 20, 218-225.
27. Wurtman RJ, CansevM, Ulus IH (2009) Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging 13, 189-197.
28. Fornai F, Busceti CL, Ferrucci M, Lazzeri G, Ruggieri S (2002) Is there a role for uridine and pyrimidine nucleosides in the treatment of vascular dementia?. Funct Neurol 17, 93-99.
29. Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E (2010) Citicoline, use in cognitive decline: Vascular and degenerative. J Neurol Sci 299, 188-192.
30. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM, Lozano R (2002) Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke 33, 2850-2857.
31. Martin DS, Stolfi RL, Sawyer RC (1989) Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24, 9-14.
32. Wurtman RJ, Regan M, Ulus I, Yu L (2000) Effect of oral CDP-choline on plasma choline and uridine levels in human. Biochem Pharmacol 60, 989-992.
33. Kelsen DP, Martin D, O'Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15, 1511-1517.
34. Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG,Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncology 18, 167-177.
35. Naviaux RK, McGowan KA, Barshop BA, Nyhan W, Haas R (2001) Correction of renal tubular acidosis (RTA) in mitochondrial disease patients treated with triacetyluridine (PN401). Mitochondrion 1, 107.
36. Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, MillerGW(2007) Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci 95, 196-204.
37. Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol Dis 24, 455-465.
38. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
39. Lewis J, DicksonDW, Lin WL, Chisholm L, Corral A, Jones G,Yen SH, Sahara N, Skipper L,Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
40. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5161-5166.
41. Ognibene E, Middei S, Daniele S, Adriani W, Ghirardi O, Caprioli A, Laviola G (2005) Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 156, 225-232.
42. Gil-Bea FJ, Aisa B, Schliebs R, Ramirez MJ (2007) Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav Neurosci 121, 340-344.
43. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25, 8898-8902.
44. Zhuo JM, Pratico D (2010) Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J 24, 3895-3902.
45. Dodart JC, Mathis C, Ungerer A (1997) Scopolamineinduced deficits in a two-trial object recognition task in mice. Neuroreport 8, 1173-1178.
46. Winters BD, Saksida LM, Bussey TJ (2006) Paradoxical facilitation of object recognition memory after infusion of scopolamine into perirhinal cortex: Implications for cholinergic system function. J Neurosci 26, 9520-9529.
47. EichenbaumH(1998) Using olfaction to study memory. Ann N Y Acad Sci 855, 657-669.
48. Wrenn CC, Kinney JW, Marriott LK, Holmes A, Harris AP, Saavedra MC, Starosta G, Innerfield CE, Jacoby AS, Shine J, Iismaa TP, Wenk GL, Crawley JN (2004) Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur J Neurosci 19, 1384-1396.
49. Macknin JB, Higuchi M, Lee VM, Trojanowski JQ, Doty RL (2004) Olfactory dysfunction occurs in transgenic mice overexpressing human tau protein. Brain Res 1000, 174-178.
50. Bacon AW, BondiMW, Salmon DP,Murphy C (1998) Very early changes in olfactory functioning due to Alzheimer's disease and the role of apolipoprotein E in olfaction. Ann N Y Acad Sci 855, 723-731.
51. Luo AH, Cannon EH,Wekesa KS, Lyman RF, Vandenbergh JG, Anholt RR (2002) Impaired olfactory behavior in mice deficient in the alpha subunit of G(o). Brain Res 941, 62-71.
52. Carpenter MK, Cui X, Hu ZY, Jackson J, Sherman S, Seiger A, Wahlberg LU (1999) In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol 158, 265-278.
53. Yakes FM, Van Houten B (1997) Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A 94, 514-519.
54. Rothfuss O, Gasser T, Patenge N (2010) Analysis of differentialDNAdamage in the mitochondrial genome employing a semi-long run real-time PCR approach. Nucleic Acids Res 38, e24.
55. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, FlavellRA(2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687.
56. Geiger A, Yamasaki S (1956) Cytidine and uridine requirement of the brain. J Neurochem 1, 93-100.
57. Roberts CA, Kreisman NR, Waltman M (1974) Uridine anticonvulsant effects: Selective control of nucleoside incorporation in experimental epilepsy. Epilepsia 15, 479-500.
58. Chen TH,WangMF, LiangYF,KomatsuT, Chan YC, Chung SY, Yamamoto S (2000) A nucleoside-nucleotide mixture may reduce memory deterioration in old senescenceaccelerated mice. J Nutr 130, 3085-3089.
59. Holguin S, Martinez J, Chow C,Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22, 3938-3946.
60. Ruthrich HL, Wetzel W, Matthies H (1983) Memory retention in old rats: Improvement by orotic acid. Psychopharmacology 79, 348-351.
61. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, DicksonDW,Davies P, HuttonM(2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25, 402-405.
62. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
63. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28, 13805-13814.
64. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31, 700-711.
65. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66, 435-440.
66. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74, 467-474.
67. Saydoff J, Sheng J, Hu Z, Gonzalez A, Liu L, Brenneman D, Garcia RAG, Cardin S, von Borstel R (2005) PN401 decreases neurodegeneration in models of Alzheimer's, Huntington's and Parkinson's disease, neuroinflammation, excitotoxicity and has antiepileptic activity. Alzheimers Dement 1, s68.
68. Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66, 631-645.
69. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.
70. Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) A{beta} oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30, 11938-11950.
71. Ohsawa I, Nishimaki K, MurakamiY, SuzukiY, Ishikawa M, Ohta S (2008) Age-dependent neurodegeneration accompanying memory loss in transgenic mice defective in mitochondrial aldehyde dehydrogenase 2 activity. J Neurosci 28, 6239-6249.
72. Hunsaker MR, Lee B,Kesner RP (2008) Evaluating the temporal context of episodic memory: The role ofCA3and CA1. Behav Brain Res 188, 310-315.
73. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD (2005) F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7, 269-275.
74. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21, 4183-4187.
75. Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW (2008) Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 5, 13.
76. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
77. Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, ButterfiledDA, BanksWA(2009) Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 23, 507-517.
78. Marchesi VT (2011) Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J 25, 5-13.
79. Rocchi A, Orsucci D, Tognoni G, Ceravolo R, Siciliano G (2009) The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr Alzheimer Res 6, 224-237.
80. Shiino A, Matsuda M, Handa J, Chance B (1998) Poor recovery of mitochondrial redox state in CA1 after transient forebrain ischemia in gerbils. Stroke 29, 2421-2424.
81. Akiho H, Iwai A, Katoh-Suodh M, Tsukamoto S,Koshiya K, Yamaguchi T (1997) Post-ischaemic treatment with orotic acid prevents neuronal injury in gerbil brain ischaemia. Neuroreport 8, 607-610.
82. Rosenfeldt FL, Richards SM, Lin Z, Pepe S, Conyers RA (1998) Mechanism of cardioprotective effect of orotic acid. Cardiovasc Drugs Ther 12(Suppl 2), 159-170.
83. Parker WD, Jr., Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303.
84. Barger SW, Fiscus RR, Ruth P, Hofmann F, Mattson MP (1995) Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J Neurochem 64, 2087-2096.
85. Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S (1997) Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231, 113-117.
86. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD, Jr., Bennett JP, Jr. (2000) Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 48, 148-155.
87. Bao L, AvshalumovMV, Rice ME (2005) Partial mitochondrial inhibition causes striatal dopamine release suppression and medium spiny neuron depolarization via H2O2 elevation, not ATP depletion. J Neurosci 25, 10029-10040.
88. Van Houten B, Woshner V, Santos JH (2006) Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 5, 145-152.
89. Jana A, Pahan K (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem 279, 51451-51459.
90. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408.
91. Ravasz E, Somera AL, MongruDA, Oltvai ZN, BarabasiAL (2002) Hierarchical organization of modularity in metabolic networks. Science 297, 1551-1555.
92. Guarneri P, Guarneri R, La Bella V, Piccoli F (1985) Interaction between uridine and GABA-mediated inhibitory transmission: Studies in vivo and in vitro. Epilepsia 26, 666-671.
93. Kimura T, Ho IK, Yamamoto I (2001) Uridine receptor: Discovery and its involvement in sleep mechanism. Sleep 24, 251-260.
94. Dobolyi A, Juhasz G, Kovacs Z, Kardos J (2011) Uridine function in the central nervous system. Curr Top Med Chem 11, 1058-1067.
95. Balestri F, Giannecchini M, Sgarrella F, Carta MC, Tozzi MG, Camici M (2007) Purine and pyrimidine nucleosides preserve human astrocytoma cell adenylate energy charge under ischemic conditions. Neurochem Int 50, 517-523.
96. Stout JR, Graves BS, Smith AE, Hartman MJ, Cramer JT, Beck TW, Harris RC (2008) The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): A double-blind randomized study. J Int Soc Sports Nut 5, 21.
97. Loffler M, Jockel J, Schuster G, Becker C (1997) Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 174, 125-129.
98. Balcarek K, Venhoff N, Deveaud C, Beauvoit B, Bonnet J, Kirschner J, Venhoff AC, Lebrecht D, Walker UA (2010) Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 55, 550-557.
99. Neary JT, RathboneMP, Cattabeni F, AbbracchioMP, Burnstock G (1996) Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19, 13-18.
100. MullerT, Grimm M, deVieiraRP, Cicko S, DurkT, Sorichter S, Zissel G, Idzko M (2010) Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation. Clin Exp Allergy 40, 1552-1560.
101. Amante DJ, Kim J, Carreiro ST, Cooper AC, Jones SW, Li T, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Ferrante RJ, Rusche J (2010) Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice. Amyotroph Lateral Scler 11, 520-530.